Galatek
Category: Robotics / Embodied AI
A Singapore-based automation and AI startup providing integrated vision, robotics, and software solutions to accelerate digital transformation in life sciences and semiconductor manufacturing. Galatek was founded in 2025. The company is led by David Tian. Based in Singapore. Team size: 50-100. Total funding raised: $30M. Latest round: Series A. Key investors include Undisclosed investors (Series A, Dec 2025).
- Founded
- 2025
- Headquarters
- Singapore
- Team size
- 50-100
- Total funding
- $30M
Value proposition
Delivers extreme precision and reliability by deeply integrating vision AI with motion control, automating complex scientific workflows (like brain organoid research), and unifying fragmented lab data into actionable insights.
Products and solutions
["InteVega AI Vision Platform (500+ self-developed vision/AI operators)","Abio Software Platform (Unifies ELN, LIMS, SDMS, and automation)","Intelligent AGV Robots (Collaborative mobile robots for material transfer)","Laser Dicing & Marking Machines","Smart Lab Automation Solutions"]
Unique value
Distinguishes itself through the 'Abio' platform which creates a cloud-agnostic, extensible architecture that unifies typically siloed lab data systems (ELN, LIMS) with physical automation hardware.
Target customer
Pharmaceutical companies, biotech research institutions, semiconductor manufacturers (advanced packaging), and clinical diagnostic labs.
Industries served
["Life Sciences (Drug Discovery, Synthetic Biology)","Semiconductor Manufacturing (Advanced Packaging)","Clinical Diagnostics","Smart Laboratories"]
Technology advantage
Leverages a proprietary library of over 500 2D/3D vision algorithms combined with deep learning to achieve micron-level precision in both semiconductor packaging and delicate biological sample handling.
How they differentiate
Leverages the proprietary 'InteVega' AI vision platform (derived from MegaRobo) to bridge high-precision semiconductor inspection with complex life science workflows (e.g., organoid handling), unified by the 'Abio' software layer.
Main competitors
["Automata","HighRes Biosolutions","Cognex"]
Key partnerships
National University of Singapore (NUS) - co-created next-generation smart labs
Notable customers
Top-tier global pharmaceutical firms; Research institutions
Major milestones
["Secured $30M Series A funding in Dec 2025 to accelerate global expansion","Formed strategic collaboration with a:head bio AG in Oct 2025 for brain organoid automation","Established as a Singapore-based entity (linked to MegaRobo Technologies) to target international markets"]
Growth metrics
Series A $30M raised (Dec 2025); R&D centers in Singapore, Germany, US, Japan, China; Delivery centers in Malaysia and US; Regional teams in Europe, North America, Southeast Asia
Market positioning
Global-facing automation challenger (spin-off/subsidiary of MegaRobo) targeting high-value R&D and advanced packaging sectors.
Geographic focus
Global (HQ in Singapore, R&D/Operations in Germany, US, Japan, China)
Patents and IP
Proprietary 'InteVega' vision algorithms and 'Abio' software architecture
About David Tian
RIGOL Technologies; B.S. Electrical Engineering, Shandong Normal University (2003-2007)